Roche has asked the European Medicines Agency to fast-track its planned EU marketing authorization application (MAA) for another of its investigational T-cell engaging bispecific antibodies, glofitamab.
Roche Seeks Speedy EU Review For Second Bispecific Antibody
The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.
